• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data
    • FAQs

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • FAQs
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status

May 8, 2017

Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078

Apr 25, 2017

SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID

Apr 21, 2017

SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 12, 2017

SCYNEXIS, Inc. to Present at the 16th Annual Needham Healthcare Conference

Mar 29, 2017

SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update

Mar 13, 2017

SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference

Mar 7, 2017

SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request

Mar 2, 2017

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

Jan 31, 2017

SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors

Jan 26, 2017
RSS
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2021 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us